Molnupiravir Manufacturer
Molnupiravir (development codes MK-4482 and EIDD-2801) is an orally active experimental antiviral medication that was designed to treat viruses. It is a class of drug of the synthetic nucleoside derivative N4-hydroxycytidine that works against viruses by causing copying errors during viral RNA replication.
Molnupiravir 200 mg Capsules
Molnupiravir Manufacturer
Molnupiravir (development codes MK-4482 and EIDD-2801) is an orally active experimental antiviral medication that was designed to treat viruses. It is a class of drug of the synthetic nucleoside derivative N4-hydroxycytidine that works against viruses by causing copying errors during viral RNA replication.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.
